Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
13 studies found for:    "B cell prolymphocytic leukemia"
Show Display Options
Rank Status Study
1 Terminated Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: alvespimycin hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
2 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
3 Active, not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
Conditions: Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate
4 Active, not recruiting Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Biological: Ofatumumab;   Other: Pharmacological Study
5 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-Cell Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
6 Recruiting PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: anti-CD19 CAR-NK cells
7 Recruiting Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: PCAR-019 (anti-CD19 CAR-T cells)
8 Recruiting CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Conditions: Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Mantle Cell Lymphoma;   B-cell Prolymphocytic Leukemia;   Diffuse Large Cell Lymphoma
Intervention: Biological: PCAR-019 (anti-CD19 CAR-T cells)
9 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
10 Active, not recruiting Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia
Interventions: Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Radiation: Total-Body Irradiation
11 Recruiting Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies
Conditions: B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Biological: XmAb13676
12 Withdrawn Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
Conditions: Lymphoproliferative Malignancies;   Acute Myeloid Leukemia
Intervention: Drug: ZEN003365
13 Recruiting Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Condition: Leukemia
Intervention: Drug: Nelarabine

Study has passed its completion date and status has not been verified in more than two years.